SBC Medical Group (NASDAQ:SBC) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

SBC Medical Group (NASDAQ:SBC) announced its quarterly earnings results on Thursday. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $0.01, FiscalAI reports. SBC Medical Group had a net margin of 29.37% and a return on equity of 20.76%. The business had revenue of $43.06 million for the quarter, compared to analyst estimates of $41.66 million.

Here are the key takeaways from SBC Medical Group’s conference call:

• Q1 2026 revenue was $43 million, down 9% year over year, but management said the decline was mainly due to prior fee-structure revisions and a one-time gain in the prior-year quarter.
• Excluding the fee-structure impact and AHH consolidation timing, management said underlying revenue grew 111% YoY and underlying EBITDA grew 117% YoY, highlighting strong core growth.
• Management said clinic traffic, repeat visits, and average spend per visit improved, and that competitive pressure in the Japanese and global aesthetics market has eased somewhat.
• The company expects margins to remain stable and improve over time, supported by AI initiatives aimed at boosting customer experience and lowering labor and operating costs.
• On capital allocation, SBC Medical said growth investment and disciplined M&A remain the priority, while share buybacks are not a high priority right now and the company is focused instead on improving liquidity and float.

SBC Medical Group Trading Down 7.7%

NASDAQ:SBC traded down $0.25 during trading hours on Thursday, hitting $2.98. 175,307 shares of the company were exchanged, compared to its average volume of 191,541. The company has a fifty day simple moving average of $3.77 and a 200 day simple moving average of $3.94. SBC Medical Group has a one year low of $2.95 and a one year high of $5.75. The stock has a market capitalization of $305.69 million, a price-to-earnings ratio of 6.08 and a beta of 0.61. The company has a current ratio of 3.78, a quick ratio of 3.74 and a debt-to-equity ratio of 0.13.

Insider Transactions at SBC Medical Group

In related news, CEO Yoshiyuki Aikawa sold 4,422,900 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $2.12, for a total transaction of $9,376,548.00. Following the transaction, the chief executive officer directly owned 861,600 shares of the company’s stock, valued at approximately $1,826,592. This represents a 83.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 7,987,900 shares of company stock valued at $20,142,848 over the last quarter. 89.47% of the stock is currently owned by insiders.

Hedge Funds Weigh In On SBC Medical Group

Hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. increased its position in shares of SBC Medical Group by 292.0% during the fourth quarter. Russell Investments Group Ltd. now owns 11,775 shares of the company’s stock valued at $51,000 after acquiring an additional 8,771 shares during the last quarter. Barclays PLC increased its stake in shares of SBC Medical Group by 123.7% during the 4th quarter. Barclays PLC now owns 17,779 shares of the company’s stock worth $77,000 after purchasing an additional 9,831 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of SBC Medical Group by 91.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 27,341 shares of the company’s stock worth $118,000 after purchasing an additional 13,074 shares during the period. Wells Fargo & Company MN grew its holdings in SBC Medical Group by 195.1% during the fourth quarter. Wells Fargo & Company MN now owns 12,626 shares of the company’s stock valued at $54,000 after purchasing an additional 8,348 shares during the period. Finally, Nuveen LLC purchased a new stake in SBC Medical Group in the fourth quarter worth $53,000. Institutional investors own 60.82% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on SBC shares. Weiss Ratings raised shares of SBC Medical Group from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 8th. Wall Street Zen raised SBC Medical Group to a “hold” rating in a research report on Saturday, May 9th. Finally, BTIG Research initiated coverage on SBC Medical Group in a research note on Friday, March 6th. They set a “buy” rating and a $8.00 price objective on the stock. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, SBC Medical Group presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

About SBC Medical Group

SBC Medical Group, Inc is a publicly traded healthcare management services company listed on the Nasdaq under the ticker SBC. The company specializes in supporting in-office ancillary service providers by offering a suite of administrative and operational solutions designed to streamline practice management and enhance revenue performance. Its core mission is to help physician practices, imaging centers and other ancillary service providers focus on patient care while outsourcing complex back-office functions.

The company’s primary offerings include revenue cycle management, medical billing and coding, compliance oversight and transcription services.